Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”

You may also be interested in...



Health, Beauty And Wellness News: Launches, Petition, Recalls, Ad Campaign, 'Irreparably Defective' SOP

Earth Mama offers mineral sunscreens; AHPA petitions for pullulan, adds Sustainability Subcommittee; POM Wonderful campaigns with 'Worry Monsters'; Herbalife perks iced protein; 'Disposal/Destruction of Irreparably Defective Articles' SOP draft ready; King Bio-linked homeopathic recalls expand; and Forager recalls protein shakes.

Imposing RCTs For Supplement Claims Would Cause 'Wholesale Change' In Regulation – CRN, CHPA

“The industry would face confusion as to the appropriate substantiation standard for non-disease dietary supplement claims,” say the Council for Responsible Nutrition and the Consumer Healthcare Products Association in a joint amicus brief filed with in Second Circuit. They submitted the brief in support of Quincy’s motion urging the appeals court to dismiss an appeal by FTC and New York of a federal district court’s 2017 dismissal of the federal and state agencies' complaint against Quincy.

Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads

An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel